OSTAR is a company dedicated to incorporating AI into the development of medical devices. OSTAR Biotech was founded with the goal of early warning for heart attacks and strokes, utilizing AI technology to address cardiovascular diseases, the leading cause of death worldwide.
OSTAR Biotech developed the world’s most advanced cardiac disease algorithm, the "AI-Powered Cardiac Disease Early Warning Technology." In 2020, this technology won first place in the IT/Electrical category of the R&D 100 Awards, a prestigious U.S. technology award. The technology can detect acute arrhythmias and atrial fibrillation (AF), holds patents in both the U.S. and Taiwan, and has undergone clinical trials in Taiwan's teaching hospitals, achieving 96.68% sensitivity, 90.53% specificity, and 93.76% accuracy in detecting AF. The OSTAR oximeter, which employs this AI technology, provides rapid and accurate cardiac data, capable of measuring oxygen levels, heartbeats, and waveform signals.
The "Cloud Multi-Function Patient Monitor" won the "Drug and Technology Research and Development Award" (Gold Award in Medical Device Category) from the Ministry of Health and Welfare and the Ministry of Economic Affairs. This is the only national-level honor jointly organized by central authorities in Taiwan.
The "Cardiac Spectrum Blood Pressure Monitor" won the "Drug and Technology Research and Development Award" (Bronze Award in Medical Device Category) from the Ministry of Health and Welfare and the Ministry of Economic Affairs. This device uses OSTAR's AI heart disease algorithm and features AI automatic calibration, eliminating the need for factory recalibration.